Free Trial

Ceapro Q1 2024 Earnings Report

Ceapro logo
C$0.22 -0.03 (-11.76%)
(As of 05/31/2024)

Ceapro EPS Results

Actual EPS
-C$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ceapro Revenue Results

Actual Revenue
$2.77 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ceapro Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

Ceapro Earnings Headlines

Ceapro (CVE:CZO) Stock Price Down 11.8% - Time to Sell?
2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis
Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.
See More Ceapro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ceapro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ceapro and other key companies, straight to your email.

About Ceapro

Ceapro (CVE:CZO), a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

View Ceapro Profile

More Earnings Resources from MarketBeat

Upcoming Earnings